ArticleiScience2025

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.

Rachel A Bender Ignacio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.